CDX2 and colorectal carcinoma: These findings suggest that curcumin inhibits EMT in CRC by epigenetically reactivating CDX2 through demethylation of its promoter, thereby downregulating the CDX2/Wnt3a/β-catenin axis and restoring epithelial characteristics.